about
A longitudinal study examining adherence to guidelines in diabetes care according to different definitions of adequacy and timelinessPractical combination therapy based on pathophysiology of type 2 diabetesChanging the treatment paradigm for type 2 diabetes.Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient- and physician-related factors): A prospective observational DIPP-FACTOR study in KoreaSecondary failure of metformin monotherapy in clinical practice.Current status of management, control, complications and psychosocial aspects of patients with diabetes in India: Results from the DiabCare India 2011 Study.[Efficacy and tolerability of sitagliptin in type 2 diabetic patients inadequately controlled with metformin. A prospective observational study in austrian primary care].Identifying and meeting the challenges of insulin therapy in type 2 diabetes.Pro's and con's of the early use of insulin in the management of type 2 diabetes: a clinical evaluation.Lessons from models of pancreatic beta cells for engineering glucose-sensing cellsPioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment.Drug titration patterns and HbA 1c levels in type 2 diabetes.Efficacy and safety of saxagliptin as add-on therapy in type 2 diabetes.Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology.Diabetes & coronary heart disease: current perspectives.Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trialShould malaria treatment be guided by a point of care rapid test? A threshold approach to malaria management in rural Burkina Faso.Loss of glycemic control in patients with type 2 diabetes mellitus who were receiving initial metformin, sulfonylurea, or thiazolidinedione monotherapy.Optimizing care and outcomes for people with type 2 diabetes - lessons from a translational research program on insulin initiation in general practice.An overview of management issues in adult patients with type 2 diabetes mellitus.Provider beliefs about diabetes treatment have little impact on glycemic control of their patients with diabetesEffects of initiation and titration of a single pre-prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6-month 'proof-of-concept' study.Minimizing Hypoglycemia and Weight Gain with Intensive Glucose Control: Potential Benefits of a New Combination Therapy (IDegLira).Delay in starting insulin after failure of other treatments in patients with type 2 diabetes mellitus.Delay of insulin addition to oral combination therapy despite inadequate glycemic control: delay of insulin therapy.Grand challenges in diabetesRole of impaired insulin secretion and insulin resistance in the pathogenesis of type 2 diabetes mellitus.Use of an Electronic Medical Record (EMR) to Identify Glycemic Intensification Strategies in Type 2 Diabetes.Do Web-Based Interventions Improve Well-Being in Type 2 Diabetes? A Systematic Review and Meta-Analysis.Factors influencing initial choice of insulin therapy in a large international non-interventional study of people with type 2 diabetesInhaled insulin for controlling blood glucose in patients with diabetesAssociation of more negative attitude towards commencing insulin with lower glycosylated hemoglobin (HbA1c) level: a survey on insulin-naïve type 2 diabetes mellitus Chinese patients.Achieving fasting and postprandial blood glucose control in type 2 diabetes.Primary care physician beliefs about insulin initiation in patients with type 2 diabetesShould A1C targets be individualized for all people with diabetes? Arguments for and against.Lixisenatide: A New Member of the Glucagon-Like Peptide 1 Receptor Agonist Class of Incretin Therapies.Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet.Dipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitus.AIR Inhaled Insulin System: a novel insulin-delivery system for patients with diabetes.
P2860
Q21135236-4BD7289E-AAC2-4236-93C5-35A2B82542A5Q28076530-C7740557-7470-4D40-8B00-3D55EF64580FQ33610676-EC5F19EB-2C50-42B3-BEB9-C0A3FFF16443Q33633601-BB9AA3C1-A54D-430E-9C23-7CFFD39F3968Q33683607-629DD047-FA26-42FA-9586-7843988985B2Q33750472-C627D693-3A72-4D94-AEF5-E7CCFA079B66Q33858415-3E04786B-0521-4B0A-B1E3-D938EA123EA4Q33863413-F6A3A2C4-E448-484B-8891-3504AEC17E79Q33980529-A92B6859-95E9-44FB-BFC5-22F1B95BD221Q34054232-9223B276-2AF7-4D18-A9EF-940C16E0A3C7Q34139048-BBCD0E87-0033-4C72-9441-8DE0D9892B4AQ34322132-D4451920-1967-4A94-B56F-AC7FDC5624B6Q34454269-436307BC-9ACC-4490-9E4C-05D58F7F4D83Q34479807-B93BB3DD-2929-478B-90C1-9A20E69385C4Q34530098-3C87D871-A0CC-455B-A990-78B18D1DDBD3Q34592210-00A22BB6-7778-4A3D-867E-8AA943595A98Q34610019-1DF95419-ACBD-4606-9085-9DFDAB3D38ECQ34614614-B3678B64-594F-4D77-A7B6-CED5AD65A99CQ34656261-76898711-6277-4B36-9401-97775D4FBAD1Q35026090-5F351B3E-ADB6-4984-BBD6-F40C7A52FB72Q35075959-71799E0F-FBAE-4676-8B0C-9661B480A494Q35126777-19722375-FD84-425F-9306-13DE8C0E0885Q35589774-C9347F93-CACD-4CBF-ACB1-5C030DB77893Q35666228-A467045C-CD9A-4467-99CC-B56C0454CA3AQ35678285-D5033E46-D18C-4198-946F-F789EDEF7A76Q35691530-FB60A01B-E77E-4C08-A5F3-FDBF96C240B6Q35971224-4BFD31BD-837B-42BA-9A0D-3572C593E5F4Q36131766-79A259CB-1FF5-4539-9BDA-4BC6618126E4Q36159023-30C3EFDE-0008-4F83-AEF0-3BE6F653042CQ36171763-B5BCF98C-85E3-4370-9FE2-18D61F98F2BEQ36303804-12E32ED7-6229-4064-8B4D-66833B790214Q36596878-2124B656-54F9-4CAB-BA12-02ADDAC8A1F3Q36611551-DB48FDD1-818D-4BFD-8506-4A6847AA9918Q36636422-68B114B6-7B92-4CAB-808D-CC2552C46217Q36691574-E349BBBA-FCCE-4996-9978-AA7FE55AAC3DQ36783760-1B1CB58D-4749-4EBD-900F-F31BE9A64986Q36803151-1E8CE638-2B7D-4B6A-A7B6-E46597A6410CQ36835802-EA0C9C84-808D-4419-8E4E-DF68F7D37967Q36892807-4F41E021-8406-482D-BA30-99AD4278620BQ36938359-9642287A-B355-451E-872F-0E8734E228BA
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
The burden of treatment failure in type 2 diabetes.
@en
type
label
The burden of treatment failure in type 2 diabetes.
@en
prefLabel
The burden of treatment failure in type 2 diabetes.
@en
P2093
P1433
P1476
The burden of treatment failure in type 2 diabetes.
@en
P2093
Andrew Perry
Gregory A Nichols
Jonathan B Brown
P304
P356
10.2337/DIACARE.27.7.1535
P407
P577
2004-07-01T00:00:00Z